|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011306,
umls-concept:C0085358,
umls-concept:C0087111,
umls-concept:C0149615,
umls-concept:C0249989,
umls-concept:C0392756,
umls-concept:C0856825,
umls-concept:C1167395,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1517004,
umls-concept:C1706438,
umls-concept:C1709854,
umls-concept:C2003941,
umls-concept:C2698600
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-2-25
|
|
pubmed:abstractText |
Recent evidence suggests that dendritic cells (DCs) can regulate and amplify immune responses. Flt3 ligand (FL)-derived DC function was tested as a stimulator of allogeneic lymphocytes in vitro and in vivo. Treatment of mice with FL dramatically expanded DC number, but DCs isolated from FL-treated mice (FL DCs) were poor stimulators of allogeneic T-cell responses in vitro. Further activation of FL DCs did not restore their stimulatory ability, and FL DCs did not suppress the stimulation of the allogeneic T cells by normal DCs. FL treatment significantly increased the CD8 alpha(+) DC subset, which appeared to be the reason for their poor stimulatory capacity. These observations were confirmed in vivo using a mouse model of acute graft-versus-host disease (GVHD) wherein host DCs play a critical role. FL treatment of recipients before allogeneic bone marrow transplantation dramatically suppressed donor T-cell responses to host antigens, thereby reducing GVHD mortality (P <.01). These data represent a novel strategy that alters host DCs and reduces acute GVHD.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1825-32
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11861301-Acute Disease,
pubmed-meshheading:11861301-Adjuvants, Immunologic,
pubmed-meshheading:11861301-Animals,
pubmed-meshheading:11861301-Antigens, CD8,
pubmed-meshheading:11861301-Bone Marrow Transplantation,
pubmed-meshheading:11861301-Cell Division,
pubmed-meshheading:11861301-Coculture Techniques,
pubmed-meshheading:11861301-Dendritic Cells,
pubmed-meshheading:11861301-Disease Models, Animal,
pubmed-meshheading:11861301-Female,
pubmed-meshheading:11861301-Graft vs Host Disease,
pubmed-meshheading:11861301-Lymphocyte Activation,
pubmed-meshheading:11861301-Membrane Proteins,
pubmed-meshheading:11861301-Mice,
pubmed-meshheading:11861301-Mice, Inbred C57BL,
pubmed-meshheading:11861301-Survival Rate,
pubmed-meshheading:11861301-T-Lymphocytes,
pubmed-meshheading:11861301-Transplantation, Homologous
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Michigan Cancer Center, Ann Arbor, 48109-0942, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
